Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01507311
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    A single dose injected subcutaneously (under the skin)
  • placebo — DRUG
    A single dose injected subcutaneously (under the skin)

Study Details

This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.

Key Dates

Start date
Sep 30, 1999
Status verified
Jan 2017
Primary completion
Dec 31, 1999
Completion
Dec 31, 1999

Study Design

Enrollment
11 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: NNC 90-1170
  • Placebo Comparator: Placebo

Primary Outcome Measure

Insulin secretory burst mass

Related Studies